论文部分内容阅读
肾功能异常可增加心房颤动发病率,透析的心房颤动患者卒中风险和出血风险显著升高。抗凝治疗可降低心房颤动患者卒中风险,华法林是临床常用口服抗凝药,在透析的心房颤动患者中使用华法林能否获益仍存在争议。本文汇总了近年来华法林在透析的心房颤动患者中的研究,分析了各国心房颤动抗凝指南的建议,旨在为华法林在透析的心房颤动患者中合理应用提供参考。
Renal dysfunction increases the incidence of atrial fibrillation, and the risk of stroke and bleeding in dialysis patients with atrial fibrillation is significantly increased. Anticoagulant therapy can reduce the risk of stroke in patients with atrial fibrillation. Warfarin is a commonly used oral anticoagulant. Whether or not warfarin can be used to benefit patients with atrial fibrillation during dialysis remains controversial. This article summarizes the recent studies of warfarin in patients with atrial fibrillation undergoing dialysis and analyzes recommendations for anticoagulation guidelines for atrial fibrillation in various countries in order to provide a reference for the rational use of warfarin in dialysis patients with atrial fibrillation.